Clinical Outcomes of Patients with a Light Adjustable Lens (LAL) in At Least One Eye

Bucci Laser Vision Institute24 enrolled

Overview

To collect data on bilateral pseudophakic patients implanted with the RxSight Light Adjustable Lens (LAL) in at least one eye

Study Type

OBSERVATIONAL

Enrollment

Conditions

IOL

Interventions

Light Adjustable LensDEVICE

The Light Adjustable Lens (LAL) is a posterior chamber, UV absorbing, three-piece, foldable, photoreactive silicone intraocular lens with a squared posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure of the implanted RxSight LAL using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change post-operatively. A subsequent lock-in exposure is delivered to the implanted LAL to stabilize the lens power.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults with bilateral pseudophakia who have been implanted with the LAL in at least one eye and who have completed LDD light treatments Exclusion Criteria: * Visually significant eye disease

Locations (1)

Bucci Laser Vision Institute

Wilkes-Barre, Pennsylvania, United States

Outcomes

Primary Outcomes

Patient Satisfaction - subjective questionnaire

Subjective questionnaire explores the frequency/need for glasses for various visual functions at distance/intermediate/near, experience with dysphotopsias, and overall satisfaction of visual function without glasses.

Time frame: 3-18 months after cataract surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.